On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal (Q38110358)

29 August 2017

title

On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal (English)

1 reference

29 August 2017

Mark J Millan

1

1 reference

29 August 2017

publication date

30 May 2013

1 reference

The International Journal of Neuropsychopharmacology

29 August 2017

published in

1 reference

29 August 2017

volume

17

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

1009-1037

1 reference

NPY intraperitoneal injections produce antidepressant-like effects and downregulate BDNF in the rat hypothalamus

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Vilazodone: in major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Mechanism of action of trazodone: a multifunctional drug

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Trace amine-associated receptors as emerging therapeutic targets

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Therapeutic options for treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Molecular adaptation to chronic antidepressant treatment: evidence for a more rapid response to the novel α₂-adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, compared to the SNRI, venlafaxine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA).

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Antidepressant-like effect of 17beta-estradiol: involvement of dopaminergic, serotonergic, and (or) sigma-1 receptor systems

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Functional biomarkers of depression: diagnosis, treatment, and pathophysiology

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Enhancement of antidepressant potency by a potentiator of AMPA receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

α7-Nicotinic receptors and cognition

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

The role of transcranial magnetic stimulation in treatment-resistant depression: a review

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Depression drug disappoints

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Genetic and epigenetic defects in mental retardation.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: Evidence from animal models

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Serum ghrelin levels and the effects of antidepressants in major depressive disorder and panic disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

The mGlu5 receptor antagonist MPEP activates specific stress-related brain regions and lacks neurotoxic effects of the NMDA receptor antagonist MK-801: significance for the use as anxiolytic/antidepressant drug

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Can we rationally design promiscuous drugs?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Sleep deprivation in depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Epigenetic dysregulation in cognitive disorders.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA methylation inhibitors.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

The hidden third: improving outcome in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Glucocorticoid antagonists in neuropsychiatric [corrected] disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Transcranial direct current stimulation for the outpatient treatment of poor-responder depressed patients.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Aberrant epigenetic landscape in intellectual disability.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Agomelatine, the first melatonergic antidepressant: discovery, characterization and development

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Polypharmacy in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Multi-target therapeutics: when the whole is greater than the sum of the parts

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Trace amine-associated receptor 1 as a monoaminergic modulator in brain

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Characterization of the potent 5-HT(1A/B) receptor antagonist and serotonin reuptake inhibitor SB-649915: preclinical evidence for hastened onset of antidepressant/anxiolytic efficacy.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its a

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Tricyclic antidepressant pharmacology and therapeutic drug interactions updated

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Overview of the Genetics of Major Depressive Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Molecular mechanisms associated with the antidepressant effects of the class I histone deacetylase inhibitor MS-275 in the rat ventrolateral orbital cortex

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Polytherapy in bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Fluoxetine, 17-β estradiol or folic acid combined with intra-lateral septal infusions of neuropeptide Y produced antidepressant-like actions in ovariectomized rats forced to swim

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

National trends in psychotropic medication polypharmacy in office-based psychiatry

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Modafinil: a review of neurochemical actions and effects on cognition

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Mecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Brain-derived neurotrophic factor and neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Is pharma running out of brainy ideas?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Cognitive enhancing effects of ghrelin receptor agonists

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Pindolol augmentation of antidepressant response

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Ketamine for treatment-resistant unipolar depression: current evidence

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonism

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Mindfulness-based stress reduction, mindfulness-based cognitive therapy, and Zen meditation for depression, anxiety, pain, and psychological distress

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Combined α7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Finding the missing heritability of complex diseases

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Ketamine for depression: where do we go from here?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

A preclinical and clinical rationale for quetiapine in mood syndromes

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Serotonin receptors, type 4: a new hope?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Epigenetic treatments for cognitive impairments

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

5-HT1 receptor augmentation strategies as enhanced efficacy: therapeutics for psychiatric disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Efficacy of light therapy for perinatal depression: a review

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

From synapse to nucleus: novel targets for treating depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

5-HT2 ligands in the treatment of anxiety and depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Antidepressant actions of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Tachykinin receptor antagonists in clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Potentially inappropriate use of psychotropic medications in hospitalized elderly patients in France: cross-sectional analysis of the prospective, multicentre SAFEs cohort

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Steric hindrance mutagenesis in the conserved extracellular vestibule impedes allosteric binding of antidepressants to the serotonin transporter

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Genes, environment, and individual differences in responding to treatment for depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Medication augmentation after the failure of SSRIs for depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

The central and basolateral amygdala are critical sites of neuropeptide Y/Y2 receptor-mediated regulation of anxiety and depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Emerging drugs for major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Exploration of structure-activity relationships for dual serotonin transporter reuptake inhibitors-histamine H3 receptor antagonists

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Can we discover pharmacological promiscuity early in the drug discovery process?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Systems genetics for drug target discovery

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Melanocortin-4 receptor antagonists for the treatment of depression and anxiety disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Emerging targets for the pharmacological treatment of depression: focus on melatonergic system

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Activation of the mGlu7 receptor elicits antidepressant-like effects in mice

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Acute ghrelin administration reverses depressive-like behavior induced by bilateral olfactory bulbectomy in mice

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Metabotropic glutamate receptors: from the workbench to the bedside

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Immune system to brain signaling: neuropsychopharmacological implications.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Circadian abnormalities, molecular clock genes and chronobiological treatments in depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Rapid-acting antidepressant strategies: mechanisms of action

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

MicroRNAs and depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Fragments, network biology and designing multiple ligands

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

The physicochemical challenges of designing multiple ligands

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Which antidepressants have demonstrated superior efficacy? A review of the evidence

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Intra-lateral septal infusions of folic acid alone or combined with various antidepressant drugs produce antidepressant-like actions in male Wistar rats forced to swim

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001496

7 January 2021

10.1017/S1461145712001496

Identifiers

DOI

1 reference

29 August 2017

1 reference